Sign in
4

Changes in Ownership

Aclaris Therapeutics, Inc. Filed Acc 0001209191-23-016063

Chief Financial Officer sold 1,894 shares at an average $12.45 ($23,579)

  • Chief Financial Officer acquired 6,450 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Balthaser Kevin Chief Financial Officer 2023-03-01 Option exercise +1,475 2,175 D
Balthaser Kevin Chief Financial Officer 2023-03-01 Option exercise +1,100 3,275 D
Balthaser Kevin Chief Financial Officer 2023-03-01 Option exercise +2,375 5,650 D
Balthaser Kevin Chief Financial Officer 2023-03-02 Sale −1,000 $12.29 $12,289 4,650 D
Balthaser Kevin Chief Financial Officer 2023-03-02 Option exercise +1,500 6,150 D
Balthaser Kevin Chief Financial Officer 2023-03-03 Sale −894 $12.63 $11,290 5,256 D
Derivatives
Balthaser Kevin Chief Financial Officer 2023-03-01 Option exercise · Restricted Stock Units −1,475 0 D
Balthaser Kevin Chief Financial Officer 2023-03-01 Option exercise · Restricted Stock Units −1,100 2,200 D
Balthaser Kevin Chief Financial Officer 2023-03-01 Option exercise · Restricted Stock Units −2,375 7,125 D
Balthaser Kevin Chief Financial Officer 2023-03-02 Option exercise · Restricted Stock Units −1,500 1,500 D
Open-market sales · 1,894 sh · avg $12.45 · $23,579
Loading xslF345X03/doc4.xml…